Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (3928)	3/15/1998 1:16:00 AM
From: Mr.Rich Nouveau	Read Replies (2) of 6136

I'm curious about the rhinovirus drug candidate. Since this (the "common cold") is an acute disease, presumably the clinical development can progress very quickly: short animal toxicology studies, quick Phase I in volunteers, quick pivotal phase III's in one cold season. Does anyone know more about this? I recall that Agouron had a deal with a drug-delivery company (Nastech?) to develop nasal delivery systems, presumably for this drug, but on their web page, Agouron talks about oral bioavailability testing of their rhinovirus inhibitors, which suggests they're going for a pill. Once again, any info on this? Finally, is there competition in this area ... or will Agouron be the first into the clinic? It seems to me that the rhinovirus drug might catch up and pass the cancer drugs (timewise) ... and has the potential to be huge as well as the potential to be a complete bust (just because the first drugs in a class always have higher risk of failure). Comments?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next